REVB Revelation Biosciences, Inc.

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. REVTx-99, its lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for complete immunity. The company is also developing REVDx-501, a rapid point-of-care diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation.

As of 12/02/2022     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  12/10/2013
Outstanding shares:  23,536,070
Average volume:  400,082
Market cap:   $5,436,832
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   0.21
PB ratio:   0.01
PS ratio:   0.00
Return on equity:   -281.98%
Net income %:   29.95%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy